OmniSeq, a subsidiary of Roswell Park Cancer Institute, received New York State Clinical Laboratory Evaluation Program (CLEP) approval for its OmniSeq Comprehensive panel, a 144-gene, pan-cancer, next-generation sequencing tumor-profiling diagnostic panel to guide oncology treatment decision-making. OmniSeq Comprehensive provides access to more than 650 therapeutic associations and 850 clinical trial associations and identifies contraindications for drugs not appropriate for a particular patient.
Carl Morrison, MD, DVM
“OmniSeq is proud to receive New York State CLEP approval for OmniSeq Comprehensive. CLEP is the highest standard of Clinical Laboratory Improvement Amendments laboratory validation,” said Carl Morrison, MD, DVM, President and Chief Scientific Officer of OmniSeq and Executive Director of the Roswell Park Center for Personalized Medicine. “OmniSeq Comprehensive’s small sample requirements—as little as one-tenth of the typical sample requirement—will enable us to generate complete results from a high proportion of precious samples. This panel enables physicians to zero in on the most important results for patient outcomes.”
Cure Forward Partnership
OmniSeq has also announced it is partnering with Cure Forward to help patients control their care and be recruited for clinical trials through its Clinical Trial Exchange. Patients can obtain their OmniSeq Comprehensive test results online and directly apply that information to understand their disease and treatment options. On Cure Forward’s platform, trial sponsors can identify patients who match their selection criteria and invite them to apply to their studies.
“Patients and their families are becoming increasingly active participants in devising strategies for their care. Precision medicine is a framework for matching patients to the particular therapies that match their condition,” said Martin Naley, Founder and Chief Strategy Officer of Cure Forward.
For more information about OmniSeq and the services it provides, visit www.omniseq.com. ■